Probi® has completed the first commercial production batches of a dairy-free Streptococcus salivarius BLIS K12 at its US manufacturing site. The new BLIS® strains will shortly be offered to customers around the world.
Probi entered a strategic partnership with New Zealand based Blis Technologies Ltd. as part of a long-term strategic collaboration in July, 2021. As part of this partnership, Probi® and Blis signed a licensing and distribution agreement. Probi is now manufacturing BLIS® strains at its recently upgraded fermentation facility in Redmond, WA and will shortly be offering these new strains to Probi’s customers around the world. In addition, the two companies are continuing to collaborate on additional research and development.
Streptococcus salivarius BLIS K12 is part of a portfolio of clinically documented bacterial strains for supporting our natural immune defense and preventing infections of the mouth and throat. The BLIS strains also contribute to a healthy set of teeth and gums. Blis Technologies’ clinically documented strains have a successful history of use in New Zealand, Australia and Asia, as well as in Europe and in North America.
Steve Preston, Probi’s Head of Fermentation stated: “The technology transfer of BLIS strains to Probi has gone smoothly and we have been able to make very rapid progress due to our sizable investments in fermentation technology and upgrades to our analytical capability. Furthermore, as part of our high throughput screening program for culture media optimization, we have been able to completely eliminate the need for dairy (milk) products in the formulation. We believe this is very helpful for customers seeking to produce allergen free probiotic products.”
Innovations in Food (& Beverage) Technology is a quarterly magazine distributed globally both in Print and Digital formats. www.innovationsfood.com. Twitter: @Innovfoodtech. Instagram: @innovationsinfoodtechnology. Linkedin: www.linkedin.com/in/terry-prior52
